Hypoxanthine-guanine phosphoribosyltransferase is dispensable for Mycobacterium smegmatis viability.
Purine metabolism plays a ubiquitous role in the physiology of Mycobacterium tuberculosis (Mtb) and other mycobacteria. The purine salvage enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT) is essential for Mtb growth in vitro; however, its precise role in Mtb physiology is unclear. Membrane-permeable prodrugs of specifically designed HGPRT inhibitors arrest the growth of Mtb and represent potential new antituberculosis compounds. Here, we investigated the purine salvage pathway in the model organism Mycobacterium smegmatis (Msm). Using genomic deletion analysis, we confirmed that HGPRT is the only guanine and hypoxanthine salvage enzyme in Msm, but is not required for in vitro growth of this mycobacterium or survival under long-term stationary phase conditions. We also found that prodrugs of Mtb HGPRT inhibitors displayed an unexpected antimicrobial activity against Msm that is independent of HGPRT. Our data point to a different mode of mechanism of action for these inhibitors than was originally supposed.Importance Purine bases, released by the hydrolytic and phosphorolytic degradation of nucleic acids and nucleotides, can be salvaged and recycled. The hypoxanthine-guanine phosphoribosyltransferase (HGPRT), which catalyzes the formation of guanosine-5'-monophosphate monophosphate from guanine and inosine-5'-monophosphate from hypoxantine, represents potential target for specific inhibitor development. Deletion of HGPRT gene in a model organism Mycobacterium smegmatis (Δhgprt Msm) confirmed that this enzyme is not essential for Msm growth. Prodrugs of acyclic nucleoside phosphonates (ANPs), originally designed against HGPRT from Mycobacterium tuberculosis (Mtb), displayed anti-Msm activities comparable to those obtained for Mtb but inhibited also Δhgprt Msm strain. These results confirmed that ANPs act in Msm by mechanism independent of HGPRT.